Earlier this year, Sarepta’s CEO bet the company would be known best for its genetic medicine advances. The latest results suggest he could be right.
Sarepta Shares Rocket 40% On Promising Early Results For Dmd Gene Therapy
MarketWatch.com - Top Stories, MarketWatch
Tue, 06/19/2018 - 10:18am
BING NEWS:
- Pharma Stock Roundup: PFE DMD Study Patient Death, FDA Panel Meet for LLY's Donanemab
Pfizer PFE reported the death of a young boy who participated in a mid-stage study of its Duchenne muscular dystrophy (“DMD”) drug, fordadistrogene movaparvovec. An FDA advisory committee meeting to ...
05/10/2024 - 4:18 am | View Link - Second Death
A young patient died due to cardiac arrest after receiving Pfizer Inc’s (NYSE:PFE) experimental gene therapy in a mid-stage trial for Duchenne muscular dystrophy (DMD), the company told in a letter to ...
05/8/2024 - 6:09 am | View Link - Sarepta DMD rival PepGen files $115m IPO
The death of a young boy with Duchenne muscular dystrophy (DMD) who was treated with Pfizer’s experimental gene therapy in a phase 2 trial has prompted the company to paus ...
02/5/2023 - 4:01 am | View Link - Myocarditis case mars Sarepta DMD gene therapy readout
New data on Sarepta's gene therapy ... dystrophy (DMD) has gone a long way towards building confidence in its efficacy – but have introduced a concern about its safety. Updated results from ...
07/6/2022 - 1:00 pm | View Link - Sarepta Bolstered by Doctor Letter Urging FDA Approval of DMD Drug
Last month, 109 members of Congress sent their own letter to the FDA urging the agency to accelerate the approval of a DMD drug, without mentioning eteplirsen by name. Sarepta shares rose 16% to $ ...
03/21/2016 - 6:07 am | View Link - More
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more